e-Article
The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
Document Type
Letter
Author
Source
Subject
*ADULTS
*LYMPHOBLASTIC leukemia
*ACUTE leukemia
*ASPARAGINASE
*FATTY liver
*OLDER people
*
*
*
*
*
Language
ISSN
1042-8194
Abstract
Among 17 patients with severe induction ASP hepatotoxicity, ten were re-challenged with ASP in subsequent cycles, of which only three patients had recurrent severe hepatotoxicity. Another real-world study found a similar median peg-ASP dose tolerated in patients >=60-years and showed preemptive peg-ASP dose reduction in patients >=60-years was associated with more successfully administered peg-ASP [[11]]. We did not observe a significant difference in hepatotoxicity rates for patients with a BMI >=30 ( I p i = 0.62), plausibly as a result of several obese patients receiving capped ASP dosing. Despite patients within our cohort having relatively few comorbidities, reflected by a low median CCI, ASP deliverability was modest; only 22 patients (47%) completed all scheduled cycles of ASP, four of whom received preemptive dose reduction. [Extracted from the article]